In this article, we will take a detailed look at 10 stocks with at least $30 million in insider spending recently. We previously covered 10 stocks with at least $20 million in insider spending recently.
Trump administration’s tariffs on goods imported from Canada and Mexico, as well as additional duties on China, took effect yesterday. As expected, the stock market reacted immediately. The technology index fell 1.2%, hitting its lowest point in almost four months, wiping out post-election gains, while blue-chip companies declined 1.5% or 650 points.
“Tariffs of these magnitude will drive both Canada and Mexico into a recession,” JP Morgan analysts wrote in their daily Tuesday note, writes The Street. Analysts added that higher costs and supply-chain disruptions will affect U.S. growth and domestic stocks. The tariffs could impact $2.2 trillion of global trade and provoke economic slowdowns in the U.S.
Many analysts have downgraded their U.S. stock projections, believing that strong earnings in 2025 may be more challenging. The broader market index is expected to finish the year around 9% higher than in 2024, but that’s still lower than the early January forecast of 12.2%.
The biggest potential positive factor, many experts are banking on, is a productivity boost from AI and expected lower interest rates. Morgan Stanley’s Andrew Slimmon suggests that the adoption of AI could lead to a productivity boom, similar to what happened with the Internet in the late 1990s.
With market fluctuations and uncertainty at play, insider trading draws attention. Executives and insiders, who possess valuable insights into company strategies, plans, and future moves, may engage in trades worth examining. For example, when a CEO or CFO invests their own money in company stock, it can signal strong confidence in the company’s potential.
Insider buying and selling can be influenced by a range of factors, so these actions should be evaluated in the broader context of a company’s financial health, industry trends, and overall market conditions. This underscores the importance of thorough research before making any investment. While insider trading activity can provide useful insights into a company’s potential, it should be considered alongside other key factors to help investors make well-informed decisions.
A close-up of a stock trader in a bustling trading floor, making a bold business decision.
Today, we’ll focus on stocks with at least $30 million in insider spending. We used Insider Monkey’s stock screener to find stocks where at least one insider purchase in the last five months was worth $30 million or more. While the total value of all insider purchases could be higher, we only looked at those over $30 million. Since more than 10 stocks met these criteria, we chose the top 10 with the largest insider purchases above $30 million.
Our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds, focusing on insider trading and stock picks from hedge fund investor newsletters and conferences. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
For each stock, we provide details on the highest individual purchase, the number of insider purchases higher than $30 million over the last three months and the company’s current market capitalization. Let’s take a look at 10 stocks with at least $30 million in insider spending recently.
10. Verde Clean Fuels, Inc. (NASDAQ:VGAS)
Highest Individual Purchase: $50,000,000.00
Number of Purchases Above $30 million: 1
Market Capitalization: $171.52 million
We begin this list of stock with hefty insider spending recently with a renewable gasoline technology company with projects in North America, Verde Clean Fuels. The Houston, Texas-based company is engaged in the deployment of its original and proprietary liquid fuels processing technology through the development of commercial production plants. Verde’s syngas-to-gasoline plus process converts syngas, derived from diverse feedstocks into fully finished liquid fuels that require no additional refining.
On January 29, one insider – Cottonmouth Ventures, LLC, a wholly-owned subsidiary of Diamondback Energy, Inc. (NASDAQ:FANG), purchased $50 million worth of Verde Clean Fuels shares at a price of $4 per share. With this purchase of 12.5 million shares, Cottonmouth Ventures increased its holdings to 14.5 million shares.
“This investment is consistent with our commitment to efficiency and sustainability in oil and gas operations,” stated Mr. Dossey, vice president of marketing at Diamondback. “Verde’s technology provides an exciting opportunity to convert associated natural gas from our Permian Basin operations into gasoline, as well as an anticipated high value outlet for a volume of our natural gas with the added potential benefit of flare mitigation and production of a lower carbon fuel.”
Currently, the stock is trading at $3.85 per share, having lost 5.41% since the beginning of the year. Over the past 12 months, Verde Clean Fuels shares dropped 18.60%.
For the quarter ended September 30, 2024, Verde Clean Fuels reported a net loss of $2.5 million, which compares to a net loss of $2.6 million in the same period of 2023. The company’s net loss for the quarter was primarily attributable to ongoing and general and administrative expenses. As of September 30, 2024, the company had cash and cash equivalents of $21.7 million and no debt.
Analyst coverage on Verde Clean Fuels is currently limited, however, the stock is also one of 10 stocks insiders spent the most money on recently.
9. Janux Therapeutics, Inc. (NASDAQ:JANX)
Highest Individual Purchase: $53,700,000.00
Number of Purchases Above $30 million: 1
Market Capitalization: $1.77 billion
Janux Therapeutics is a clinical-stage biopharmaceutical company focused on developing cancer treatments that harness the immune system to target and eliminate tumors. The San Diego, California-headquartered company has created two unique platforms: Tumor Activated T-cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). It is advancing a range of TRACTr and TRACIr treatments for solid tumors.
Currently, the company has two TRACTr therapies in clinical trials: one targets the Epidermal Growth Factor Receptor (EGFR) for colorectal, lung, head and neck, and kidney cancers, while the other targets the Prostate-Specific Membrane Antigen (PSMA) for prostate cancer. One of its leading candidates is JANX007, targeting PSMA for prostate cancer and the vasculature of other tumors.
Janux Therapeutics is also one of 10 oversold biotech stocks to buy now.
On October 18, one investor purchased $53.7 million worth of Janux Therapeutics shares for $44.75 per share. Currently, the stock is trading at $29.99 per share, having lost 43.99% year-to-date.
For the full year of 2024, the company reported a net loss of $68.99 million, compared to a net loss of $58.29 million in 2023. As of December 31, 2024, Janux Therapeutics reported cash and cash equivalents and short-term investments of $1.03 billion compared to $344.0 million on December 31, 2023.
Eleven analysts have an average “Strong Buy” rating on the stock, with a 12-month price target of $83.09, according to StockAnalysis.
8. Smithfield Foods, Inc. (NASDAQ:SFD)
Highest Individual Purchase: $64,000,000.00
Number of Purchases Above $30 million: 1
Market Capitalization: $7.77 billion
Smithfield Foods, Inc. is a global food company and one of the largest pork processors and hog producers in the world. The company went public in January of this year.
Smithfield’s extensive portfolio features well-known brands such as Smithfield, Eckrich, Nathan’s Famous, Farmland, Farmer John, and Armour. Founded in 1936 as Smithfield Packing Company, it has since grown into one of the 15 biggest agriculture stocks in 2025.
On January 29, one insider, who is a director at Smithfield acquired $64 million worth of the company’s shares for $20 per share. The stock is now trading slightly lower at $19.77 per share.
Since this is a newly listed stock, there is limited analyst coverage at the moment. Typically, professional analysis requires the stock to have been publicly traded for a certain period before it receives more attention.
7. Septerna, Inc. (NASDAQ:SEPN)
Highest Individual Purchase: $68,911,200.00
Number of Purchases Above $30 million: 1
Market Capitalization: $273.521 million
Seventh among 10 stocks with at least $30 million in insider spending recently is Septerna, a clinical-stage biotech. The South San Francisco-headquartered company is engaged in the discovery and development of G protein-coupled receptor (GPCR) oral small molecule product candidates.
Septerna is focused on three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. This is one of the 10 best rebound stocks to invest in now.
On October 28, one insider acquired $68.91 million worth of Septerna shares at a price of $18 per share. Currently, the stock is trading at $6.16 having lost 73.10% since the beginning of the year. The biggest drop in the stock’s price of 57% happened on February 18 after the company announced it would stop the Phase 1 clinical trial of SEP-786. One of its previously leading drug candidates SEP-786 targets a GPCR implicated in hypoparathyroidism. The decision came after two participants in the trial experienced an unexpected increase in bilirubin levels, which is a potential sign of liver issues. The elevated bilirubin levels were reversible, and the company did not find any evidence of serious adverse events in the trial.
For the third quarter of 2024, the company reported revenue of $176,000, which compares to revenue of $33,000 in the same period of 2023. Net loss attributable to common stockholders amounted to $20.52 million, compared to a net loss of $10.95 million in the third quarter of 2023.
Four analysts have an average “Moderate Buy” on Septerna stock, with a price target of $34, according to MarketBeat.
6. Green Brick Partners, Inc. (NYSE:GRBK)
Highest Individual Purchase: $70,346,993.08
Number of Purchases Above $30 million: 1
Market Capitalization: $2.64 billion
Green Brick Partners is a homebuilding and land development company, and one of 10 stocks with at least $30 million in insider spending recently. The Plano, Texas-based company operates in three sectors: builder operations central, builder operations southeast, and land development. It is also one of the 10 best stocks to buy according to billionaire David Einhorn.
On October 11, one insider bought $70.35 million worth of Green Brick shares at a price of $69.16 per share. Currently, the stock is trading at $59.23, having gained 4.85% since the beginning of the year.
For the full year of 2024, Green Brick disclosed total revenues of $2.1 billion, compared to $1.78 billion in 2023. Net income amounted to $417.16 million, which compares to $306.68 million in the previous year. The company also achieved a record full-year homebuilding gross margin of 33.8%, up by 290 bps year-over-year.
According to three analysts, an average rating on Green Brick stock is “Hold” with a price target of $74, writes StockAnalysis. The average price target represents an upside of 24.73% from the current price.
Over the past 12 months, the stock returned 14.50% to its investors.
5. Mach Natural Resources LP (NYSE:MNR)
Highest Individual Purchase: $79,999,995.00
Number of Purchases Above $30 million: 1
Market Capitalization: $1.65 billion
Mach Natural Resources is an independent upstream oil and gas company focused on acquiring, developing, and producing oil, natural gas, and NGL reserves in the Anadarko Basin, covering Western Oklahoma, Southern Kansas, and the Texas Panhandle. The company’s portfolio also includes midstream assets, plants, and water infrastructure.
On February 7th, Wallace William Mcmullen, a large shareholder and director at Mach Natural, purchased around $80 million worth of the company’s common units, at a price of $15.50 per unit. This acquisition was part of the company’s public offering of the company’s common units, under which Mach Natural expected to receive net proceeds of approximately $192.5 million.
Out of the 12.90 million units, McMullen acquired about 5.16 million and raised his holdings to 74.29 million company units.
The company said it plans to use the net proceeds from the offering to repay in full the approximately $23.0 million of borrowings outstanding under its super-priority credit facility, and the remainder to repay a portion of its term loan credit facility.
Later in February, Mach Natural’s board of directors declared a quarterly cash distribution for the fourth quarter of 2024 of $0.50 per unit.
Currently, the stock is trading at $14.14, having lost 17.69% year-to-date.
Three analysts have given Mach Natural an average “Strong Buy” rating with a price target of $24, according to StockAnalysis.
4. Keurig Dr Pepper Inc. (NASDAQ:KDP)
Highest Individual Purchase: $120,677,464.00
Number of Purchases Above $30 million: 1
Market Capitalization: $45.59 billion
Fourth among 10 stocks with at least $30 million in insider spending recently is a leading beverage and coffeemaker company. Previously it was known under the names Green Mountain Coffee Roasters and Keurig Green Mountain. It was created in 2018 through the merger of Keurig Green Mountain and Dr. Pepper Snapple Group.
The Burlington, Massachusetts-headquartered company offers over 125 hot and cold beverages and is home to the top-selling single-serve coffee system in the U.S. (Keurig). It has also helped Dr. Pepper become the second-largest soft drink brand in the country, surpassing Pepsi by the end of 2023.
Recently, the company revealed its new flavor lineup for 2025 in the U.S., featuring popular brands like Dr. Pepper, 7UP, A&W, and Snapple. This release follows the success of Dr. Pepper Creamy Coconut, which became the company’s most popular limited-time carbonated soft drink, and the launch of Canada Dry Fruit Splash Cherry, which topped the charts among new CSD flavor innovations in 2024.
On January 29, one insider, B.V. Holdings Maple, already a large shareholder of Keurig Dr Pepper bought $120.68 million worth of shares for $33.34 per share. With this purchase, B.V. Holdings Maple increased its holdings to 218.06 million shares.
Fourteen analysts have an average “Moderate Buy” rating with a price target of $38.23 per share. Currently, the stock is trading at $33.60, having gained 4.61% year-to-date. Over the last 12 months, Keurig Dr Pepper returned 15.50% to its investors.
For the full year of 2024, Keurig Dr Pepper reported $15.35 billion in net sales, compared to $$14.81 billion in 2023. Gross profit amounted to $8.53 billion, versus $8.08 billion in the previous year. Net income was $1.44 billion, which compares to net income of $2.18 billion in 2023.
3. Occidental Petroleum Corporation (NYSE:OXY)
Highest Individual Purchase: $153,594,511.25
Number of Purchases Above $30 million: 4
Market Capitalization: $43.7 billion
Occidental Petroleum specializes in hydrocarbon exploration in the U.S. and the Middle East, as well as petrochemical manufacturing in the U.S., Canada, and Chile. Last year, it notably grew its presence in the Permian and Midland basins through the $12 billion acquisition of Crown Rock.
In February, the company confirmed it has achieved its near-term debt repayment target of $4.5 billion in the fourth quarter of 2024 and signed two agreements in the first quarter of 2025 to divest upstream assets to undisclosed buyers for a combined total of $1.2 billion.
In March, Occidental Petroleum announced an offer to exercise its outstanding publicly traded warrants at a temporarily reduced price. This way the company enabled warrant holders to purchase one share of its commons stock at a price of $22 per share. These warrants were initially distributed by Occidental in August 2020 in the form of a dividend.
On February 2, one insider — Warren Buffett’s Berkshire Hathway Inc — bought $153.59 million worth of Occidental Petroleum shares at a price of $45.55 per share. Currently, the stock is trading at $46.53 per share, down 5.83% year-to-date. Over the past 12 months, Occidental Petroleum shares have lost 23.19%.
Seventeen analysts have an average “Hold” rating on the stock, with a price target of $60.81, according to StockAnalysis. The average price target represents a 30.69% upside from the current price.
Occidental Petroleum is also considered one of the 7 best natural resources stocks to invest in according to hedge funds.
2. Immunovant, Inc. (NASDAQ:IMVT)
Highest Individual Purchase: $336,900,200.00
Number of Purchases Above $30 million: 1
Market Capitalization: $3.14 billion
Immunovant is a biotechnology company focused on developing new treatments for autoimmune disorders. Known for its pioneering work in anti-FcRn technology, the company is creating innovative, targeted therapies aimed at improving the lives of individuals with various autoimmune diseases.
In the third quarter of 2024, Immunovant announced that five investigational new drug applications for its leading drug, IMVT-1402, had been cleared by the FDA across multiple therapeutic areas and divisions. The company also stated that it is on track to begin the registration trial for IMVT-1402 across several indications by the end of March this year.
On January 13, one insider bought $336.9 million worth of Immunovant shares for $20 per share. This way, Roivant Sciences Ltd. increased its holdings to 96.65 million shares. This purchase was part of the company’s $450 million private placement.
Currently, the stock is trading at $18.49 per share, having lost 25.35% year-to-date. Over the past 12 months, its stock price dropped 45.57%.
As of December 31, 2024, Immunovant had cash and cash equivalents amounting to $374.7 million. In the third quarter of 2024, the company reported a net loss of $111.1 million or $0.76 per share, which compares to a net loss of $51.4 million or $0.36 per share for the same quarter in 2023.
Thirteen analysts have an average “Moderate Buy” rating on Immunovant stock, with a price target of $43.35, according to MarketBeat.
Immunovant is also one of the 10 oversold pharma stocks to buy according to analysts.
1. Lucid Group, Inc. (NASDAQ:LCID)
Highest Individual Purchase: $970,894,148.86
Number of Purchases Above $30 million: 1
Market Capitalization: $6.366 billion
With a $970.89 million single investment, Lucid Group is first among 10 stocks with at least $30 million in insider spending recently. This technology company specializes in the design, engineering, manufacturing, and sale of electric vehicles (EVs), EV powertrains, and battery systems. Additionally, it creates proprietary software in-house for its Lucid vehicles. The Newark, California-based company sells its vehicles directly to consumers via its retail network and through online sales including Lucid Financial Services.
Lucid is also one of the 12 best most active stocks to buy now.
On October 10, one insider acquired $970.89 million worth of Lucid shares at a price of $2.59 per share. Currently, the stock is trading at $2.10, having lost 30.46%, since the beginning of the year.
For the full year of 2024, the company disclosed revenues of $807.83 million, compared to revenues of $595.27 million in 2023. Net loss for the year amounted to $3.06 billion, which compares to a net loss of $2.83 billion in the previous year. The company produced 9,029 vehicles in line with the 2024 annual production guidance of approximately 9,000 vehicles, and delivered 10,241 vehicles in 2024. Lucid also announced its 2025 annual production guidance of approximately 20,000 vehicles.
Overall, LCID ranks first among the 10 stocks with at least $30 million in insider spending recently. While we acknowledge the potential of LCID, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than LCID but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
